Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · IEX Real-Time Price · USD
3.10
+0.07 (2.31%)
At close: Sep 29, 2023, 4:00 PM
2.95
-0.15 (-4.84%)
After-hours: Sep 29, 2023, 4:13 PM EDT
Company Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans.
The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Milestone Pharmaceuticals Inc.
| Country | Canada |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 39 |
| CEO | Joseph G. Oliveto M.B.A. |
Contact Details
Address: 1111 Boul. Dr.-frederik-philips, Ste 420 Montreal, A8 H4M 2X6 Quebec, Canada | |
| Phone | (514) 336-0444 |
| Website | milestonepharma.com |
Stock Details
| Ticker Symbol | MIST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001408443 |
| CUSIP Number | 59935V107 |
| ISIN Number | CA59935V1076 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph G. Oliveto M.B.A. | Chief Executive Officer, President and Director |
| Amit Hasija | Chief Financial Officer and Executive Vice President of Corporate Development |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor and Member of Scientific Advisory Board |
| Jeff Nelson | Chief Operating Officer |
| Roshan Girglani | Vice President of Marketing |
| Kimberly Sheehan | Vice President of Human Resources |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor and Member of the Scientific Advisory Board |
| Dr. Guy Rousseau | SVice President of Regulatory Affairs and Quality Management |
| Lorenz Muller | Chief Commercial Officer |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 10, 2023 | 8-K | Current Report |
| Aug 10, 2023 | 10-Q | Quarterly Report |
| Jun 9, 2023 | 8-K | Current Report |
| May 31, 2023 | 424B5 | Filing |
| May 31, 2023 | 10-K/A | [Amend] Annual report |
| May 26, 2023 | EFFECT | Notice of Effectiveness |
| May 15, 2023 | S-3 | Registration statement under Securities Act of 1933 |
| May 11, 2023 | 8-K | Current Report |
| May 11, 2023 | 10-Q | Quarterly Report |
| Apr 28, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |